BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 20193458)

  • 1. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
    Wang T; Jiang CX; Li Y; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
    Maeta H; Ohgi S; Terada T
    Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma].
    Jiang HG; Gao M; Tang WP; Li FH; Cai QZ
    Ai Zheng; 2005 Sep; 24(9):1136-9. PubMed ID: 16159441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
    Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
    Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
    Yeh MW; Rougier JP; Park JW; Duh QY; Wong M; Werb Z; Clark OH
    Endocr Relat Cancer; 2006 Dec; 13(4):1173-83. PubMed ID: 17158762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
    Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
    Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
    Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.
    Patel A; Straight AM; Mann H; Duffy E; Fenton C; Dinauer C; Tuttle RM; Francis GL
    J Endocrinol Invest; 2002 May; 25(5):403-8. PubMed ID: 12035934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
    Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
    Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
    Meng XY; Zhang Q; Li Q; Lin S; Li J
    J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
    Fenton C; Patel A; Dinauer C; Robie DK; Tuttle RM; Francis GL
    Thyroid; 2000 Apr; 10(4):349-57. PubMed ID: 10807064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
    Tan H; Ye K; Wang Z; Tang H
    Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
    Zhang S; Li L; Lin JY; Lin H
    World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
    Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
    Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.
    Shi Y; Parhar RS; Zou M; Hammami MM; Akhtar M; Lum ZP; Farid NR; Al-Sedairy ST; Paterson MC
    Br J Cancer; 1999 Mar; 79(7-8):1234-9. PubMed ID: 10098765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
    Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
    Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
    Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
    Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.
    Lewy-Trenda I; Wierzchniewska-Ławska A
    Pol J Pathol; 2002; 53(3):129-32. PubMed ID: 12476614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor].
    Delektorskaia VV; Smirnova EA; Ponomareva MV; Pavlova TV; Pavlov IA
    Arkh Patol; 2010; 72(4):3-6. PubMed ID: 21086628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer.
    Tian X; Cong M; Zhou W; Zhu J; Liu Q
    J Int Med Res; 2008; 36(4):699-703. PubMed ID: 18652765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.